Products & Pipeline

We are developing and commercializing novel Digital Therapeutics for a variety of indications including smoking cessation, major depressive disorder, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity.

CT-100: Click Neurobehavioral Intervention (CNI) Platform

Product

Indication

Phase 1
Research

Phase 2
Design+PoDC

Phase 3
Pivotal Trial

Regulatory

Launch

Phase

CT-101
Clickotine

Smoking Cessation

Launch

CT-152

Major Depressive
Disorder

Phase 3

CT-141
Clickadian

Insomnia

Phase 2

CT-111
Clickheart

Acute Coronary
Syndrome

Phase 2

CT-155

Schizophrenia

Phase 2

CT-132

Migraine

Phase 2

CT-161

Overactive Bladder

Phase 1

CT-131

Chronic Lower
Back Pain

Phase 1

CT-181

Obesity

Phase 1

Clickotine

CT-101

An all in one, comprehensive digital smoking cessation program

learn more

.product__StyledBackgroundImage-sc-7d572v-2.gHMhDy:before { opacity: 1; background-image: url('/static/bb5a5fcffd5ff7354cba4fe3ef09610d/a16c9/product-list-image-1_cropped.jpg'); }

Major Depressive Disorder

CT-152

Click is researching multiple cognitive exercises for the treatment of MDD.

.product__StyledBackgroundImage-sc-7d572v-2.cCueXt:before { opacity: 1; background-image: url('/static/06fe154228271b8e6864f5c25b34c074/a16c9/product-list-image-2.jpg'); }

Clickadian

CT-141

Clickadian is under development as a clinically-validated fully digital program for insomnia

learn more

.product__StyledBackgroundImage-sc-7d572v-2.gHMhDy.gbi--1568146691-tTB7NnABRSa7QVxKnBsasX:before { opacity: 1; background-image: url('/static/6c8b392c1c5c603b7548729be0ac0fa9/a16c9/product-list-image-3.jpg'); }

Clickheart

CT-111

Clickheart is under development as a clinically-validated digital program for acute coronary syndrome

learn more

.product__StyledBackgroundImage-sc-7d572v-2.gHMhDy.gbi-672070154-bJVGzBbrGevA9cAKrHAxih:before { opacity: 1; background-image: url('/static/88d35621aeadf5f03b580bcfe16de49f/a16c9/product-list-image-6_cropped.jpg'); }

Schizophrenia

CT-155

Confidential

.product__StyledBackgroundImage-sc-7d572v-2.cCueXt.gbi--1819885946-xoLB2uuBUvEt2pmxbv9zPP:before { opacity: 1; background-image: url('/static/2370b61475dcbe66ad4e5e8b9e167a59/f155f/product-list-image-8.jpg'); }

Migraine

CT-132

CT-132 is under development as a clinically-validated digital program for migraine

learn more

.product__StyledBackgroundImage-sc-7d572v-2.gHMhDy.gbi-294741803-kgSsHCZrVSRrBmJezipog1:before { opacity: 1; background-image: url('/static/f243248b18fba3a10c5b4b0e3f60a027/a16c9/product-list-image-5.jpg'); }

Overactive Bladder

CT-161

CT-161 is under development as a clinically-validated digital program for overactive bladder

learn more

.product__StyledBackgroundImage-sc-7d572v-2.gHMhDy.gbi-1702355315-oq2cZB7dmhe8HYPYgMBRKS:before { opacity: 1; background-image: url('/static/67a6b08a934c3d9ebc1983f3ccd13f14/a16c9/product-list-image-4.jpg'); }

Obesity

CT-181

Confidential

.product__StyledBackgroundImage-sc-7d572v-2.cCueXt.gbi-651190670-kFiDpgAQMYtGBJ9uzrRB4L:before { opacity: 1; background-image: url('/static/35ac3206634a4c8949a75a1e0e9bbd4e/a7b00/product-list-image-7_cropped.jpg'); }

Additional Products in Research & Development

CT-131

Chronic Lower
Back Pain

—

Atopic
Dermatitis

—

Chronic Obstructive
Pulmonary Disease

—

Oncology

—

Osteoarthritis

—

Chronic Kidney Disease

Products in development are investigational Digital Therapeutics not for sale. FDA has not yet evaluated the safety or effectiveness of these products.